Altre lingue Salarius Pharmaceuticals, Inc.

Azioni

SLRX

US79400X4043

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 09/07/2024			Variaz. 5gg	Var. 1 gen.
2,73 ^USD	+14,71%		+23,53%	-47,50%

17/06	Dati clinici su Salarius Pharmaceuticals? Seclidemstat nei pazienti con Mds e Cmml presentati al Meeting Annuale dell'Associazione Europea di Ematologia 2024	CI
13/05	Salarius Pharmaceuticals, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting	17/06
Clinical Data on Salarius Pharmaceuticals? Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting	17/06
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split	12/06
Salarius: Q1 Earnings Snapshot	13/05
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data	25/03
Top Premarket Gainers	25/03
North American Morning Briefing : Tech in Focus on -2-	25/03
Salarius: Q4 Earnings Snapshot	22/03
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	22/03
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	22/02
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	22/02
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders	16/01
Salarius Pharmaceuticals, Inc. Announces Update on Hematologic Cancer Phase 1/2 Clinical Trial Be Conducted At the University of Texas MD Anderson Cancer Center	03/01
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment	03/01
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12
North American Morning Briefing : Stock Futures -2-	16/11
Salarius: Q3 Earnings Snapshot	10/11
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Salarius Pharmaceuticals, Inc.

Azioni

SLRX

US79400X4043

Altre lingue

Filtri